

and Treatment of HIV-Related Heart, Lung and Blood Diseases.

*Date:* April 18, 2014.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Crystal Gateway Marriott 1700 Jefferson Davis Highway Arlington, VA 22202.

*Contact Person:* Tony L Creazzo, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7180, Bethesda, MD 20892-7924, 301-435-0725, [creazzotl@mail.nih.gov](mailto:creazzotl@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS).

Dated: March 11, 2014.

**Michelle Trout,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2014-05868 Filed 3-17-14; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review Amended; Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, April 02, 2014, 01:00 p.m. to April 02, 2014, 03:00 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the **Federal Register** on March 11, 2014, 79 FR 13660.

The meeting will be held on April 7, 2014, starting at 02:00 p.m. and ending at 03:30 p.m. The meeting location remains the same. The meeting is closed to the public.

Dated: March 11, 2014.

**Michelle Trout,**

*Program Officer, Office of Federal Advisory Committee Policy.*

[FR Doc. 2014-05870 Filed 3-17-14; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is

hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* National Heart, Lung, and Blood Advisory Council.

*Date:* April 15, 2014.

*Open:* 6:00 p.m. to 9:00 p.m.

*Agenda:* Continue the February Council meeting discussion on programmatic issues.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Room 9100, Bethesda, MD 20817.

*Contact Person:* Stephen C. Mockrin, Ph.D. Director, Division of Extramural Research Activities National Heart, Lung, and Blood Institute National Institutes of Health, 6701 Rockledge Drive, Room 7100, Bethesda, MD 20892 (301) 435-0260, [mockrins@nhlbi.nih.gov](mailto:mockrins@nhlbi.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: [www.nhlbi.nih.gov/meetings/nhlbac/index.htm](http://www.nhlbi.nih.gov/meetings/nhlbac/index.htm), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS).

Dated: March 11, 2014.

**Michelle Trout,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2014-05869 Filed 3-17-14; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Availability of Draft National Toxicology Program Technical Reports; Request for Comments; Notice of Meeting

**SUMMARY:** The National Toxicology Program (NTP) announces the

availability of four draft NTP Technical Reports (TRs) scheduled for peer review: bromodichloroacetic acid, CIMSTAR 3800, green tea extract, and indole-3-carbinol. The peer-review meeting is open to the public.

Registration is requested for both public attendance and oral comment and required to access the webcast.

Information about the meeting and registration are available at <http://ntp.niehs.nih.gov/go/36051>.

**DATES:** Meeting: May 22, 2014, 8:30 a.m. to approximately 5:00 p.m. Eastern Daylight Time (EDT).

*Document Availability:* Draft TRs should be available by April 10, 2014, at <http://ntp.niehs.nih.gov/go/36051>.

*Written Public Comment*

*Submissions:* Deadline is May 8, 2014.

*Registration for Meeting, Oral*

*Comments, and/or to View Webcast:* Deadline is May 15, 2014. Registration to view the meeting via the webcast is required.

#### **ADDRESSES:**

*Meeting Location:* Rodbell Auditorium, Rall Building, NIEHS, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709.

*Meeting Web page:* The draft TRs, preliminary agenda, registration, and other meeting materials are at <http://ntp.niehs.nih.gov/go/36051>.

*Webcast:* The URL for viewing webcast will be provided to those who register.

**FOR FURTHER INFORMATION CONTACT:** Dr. Yun Xie, NTP Designated Federal Official, Office of Liaison, Policy and Review, DNTP, NIEHS, P.O. Box 12233, MD K2-03, Research Triangle Park, NC 27709. Phone: (919) 541-3436, Fax: (301) 451-5455, Email: [yun.xie@nih.gov](mailto:yun.xie@nih.gov). Hand Delivery/Courier: 530 Davis Drive, Room 2161, Morrisville, NC 27560.

#### **SUPPLEMENTARY INFORMATION:**

*Meeting and Registration:* The meeting is open to the public with time set aside for oral public comment; attendance at the NIEHS is limited only by the space available. Registration to attend the meeting in-person, provide oral comments, and/or view webcast is by May 15, 2014, at <http://ntp.niehs.nih.gov/go/36051>.

Registration is required to view the webcast; the URL for the webcast will be provided in the email confirming registration. Visitor and security information for those attending in-person is available at <http://www.niehs.nih.gov/about/visiting/index.cfm>. Individuals with disabilities who need accommodation to participate in this event should contact Dr. Yun Xie at phone: (919) 541-3436 or email: [yun.xie@nih.gov](mailto:yun.xie@nih.gov). TTY users should contact the Federal TTY Relay

Service at (800) 877-8339. Requests should be made at least five business days in advance of the event.

The preliminary agenda and draft TRs should be posted on the NTP Web site (<http://ntp.niehs.nih.gov/go/36051>) by April 10, 2014. Additional information will be posted when available or may be requested in hardcopy, see **FOR FURTHER INFORMATION CONTACT**. Following the meeting, a report of the peer review will be prepared and made available on the NTP Web site. Registered attendees are encouraged to access the meeting Web page to stay abreast of the most current information.

**Request for Comments:** The NTP invites written and oral public comments on the draft TRs. The deadline for submission of written comments is May 8, 2014, to enable review by the peer-review panel and NTP staff prior to the meeting. Registration to provide oral comments is by May 15, 2014, at <http://ntp.niehs.nih.gov/go/36051>. Public comments and any other correspondence on the draft TRs should be sent to the **FOR FURTHER INFORMATION CONTACT**. Persons submitting written comments should include their name, affiliation, mailing address, phone, email, and sponsoring organization (if any) with the document. Written comments received in response to this notice will be posted on the NTP Web site, and the submitter will be identified by name, affiliation, and/or sponsoring organization.

Public comment at this meeting is welcome, with time set aside for the presentation of oral comments on the draft TRs. In addition to in-person oral comments at the NIEHS, public comments can be presented by teleconference line. There will be 50 lines for this call; availability is on a first-come, first-served basis. The lines will be open from 8:30 a.m. until approximately 5:00 p.m. EDT on May 22, 2014, although oral comments will be received only during the formal public comment periods indicated on the preliminary agenda. The access number for the teleconference line will be provided to registrants by email prior to the meeting. Each organization is allowed one time slot per draft TR. At least 7 minutes will be allotted to each time slot, and if time permits, may be extended to 10 minutes at the discretion of the chair.

Persons wishing to make an oral presentation are asked to register online at <http://ntp.niehs.nih.gov/go/36051> by May 15, 2014, indicate whether they will present comments in-person or via the teleconference line, and indicate the TR(s) on which they plan to comment.

If possible, oral public commenters should send a copy of their slides and/or statement or talking points at that time. Written statements can supplement and may expand the oral presentation. Registration for in-person oral comments will also be available at the meeting, although time allowed for presentation by on-site registrants may be less than that for registered speakers and will be determined by the number of speakers who register on-site.

**Background Information on NTP Peer-Review Panels:** NTP panels are technical, scientific advisory bodies established on an "as needed" basis to provide independent scientific peer review and advise the NTP on agents of public health concern, new/revised toxicological test methods, or other issues. These panels help ensure transparent, unbiased, and scientifically rigorous input to the program for its use in making credible decisions about human hazard, setting research and testing priorities, and providing information to regulatory agencies about alternative methods for toxicity screening. The NTP welcomes nominations of scientific experts for upcoming panels. Scientists interested in serving on an NTP panel should provide current *curriculum vitae* to the **FOR FURTHER INFORMATION CONTACT**. The authority for NTP panels is provided by 42 U.S.C. 217a; section 222 of the Public Health Service (PHS) Act, as amended. The panel is governed by the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees.

Dated: March 10, 2014.

**John R. Bucher,**

*Associate Director, National Toxicology Program.*

[FR Doc. 2014-05895 Filed 3-17-14; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Start-Up Exclusive Patent License Agreement: Treatment of Breast Cancer, Prostate Cancer, Ewing Sarcoma, and Thymoma

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human

Services, is contemplating the grant of a Start-Up Exclusive Patent License Agreement to Paris Therapeutics, a company having a place of business in Santee, CA, to practice the inventions embodied in the following patent applications:

1. U.S. Provisional Patent Application. No. 61/474,664, filed April 12, 2011; HHS Ref. No.: E-068-2011/0-US-01; Titled: Human Monoclonal Antibodies that bind insulin-like growth factor (IGF) I and II; Inventors: Dimiter S. Dimitrov (NCI), Qi Zhao (NCI), and Zhongyu Zhu (NCI)
2. PCT Application No. PCT/US2012/033128, filed April 11, 2012; HHS Ref. No.: E-068-2011/0-PCT-02; Titled: Human Monoclonal Antibodies that bind insulin-like growth factor (IGF) I and II; Inventors: Dimiter S. Dimitrov (NCI), Qi Zhao (NCI), and Zhongyu Zhu (NCI)
3. U.S. Patent Application No. 14/111,507, filed October 11, 2013; HHS Ref. No.: E-068-2011/0-US-03; Titled: Human Monoclonal Antibodies that bind insulin-like growth factor (IGF) I and II; Inventors: Dimiter S. Dimitrov (NCI), Qi Zhao (NCI), and Zhongyu Zhu (NCI)

The patent rights in these inventions have been assigned to the Government of the United States of America. The territory of the prospective Start-Up Exclusive Patent License Agreement may be worldwide, and the field of use may be limited to "Antibodies against Insulin-like Growth Factors IGF-I and IGF-II for the treatment of breast cancer, prostate cancer, Ewing sarcoma, and thymoma."

**DATES:** Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 2, 2014 will be considered.

**ADDRESSES:** Requests for copies of the patent application(s), inquiries, comments, and other materials relating to the contemplated Start-Up Exclusive Patent License Agreement should be directed to: Whitney A. Hastings, Ph.D., Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 451-7337; Facsimile: (301) 402-0220; Email: [hastingsw@mail.nih.gov](mailto:hastingsw@mail.nih.gov). A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published or issued by the United States Patent and Trademark Office or the